E. Hwang , S. Gaito , D. Thwaites , V. Ahern , E. Smith , G. Whitfield , P. Sitch , A. France , M. Aznar
{"title":"质子治疗H&N/CNS恶性肿瘤后有严重听力损害风险的儿科患者","authors":"E. Hwang , S. Gaito , D. Thwaites , V. Ahern , E. Smith , G. Whitfield , P. Sitch , A. France , M. Aznar","doi":"10.1016/j.ijrobp.2024.11.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Recent work by the Pediatric Normal Tissue Effects in the Clinic (PENTEC) hearing loss task force provides guidance on benchmark dose constraints to reduce hearing loss but does not generate individualised risk estimations for patients. Uniquely, a risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our paediatric patient cohort treated with proton therapy (PT) for malignancies of the head and neck (H&N) or central nervous system (CNS).</div></div><div><h3>Methods</h3><div>This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 – Feb 2022 for malignancies of the H&N/CNS, either via the UK Proton Overseas Programme or at The Christie PT centre. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration.</div></div><div><h3>Results</h3><div>587 patients met inclusion criteria. Validation of the model demonstrated excellent discriminative ability, with an “optimal” cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe HI by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study.</div></div><div><h3>Conclusion</h3><div>The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e3"},"PeriodicalIF":7.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identifying Pediatric Patients at Risk of Severe Hearing Impairment After Treatment for Malignancies of the H&N/CNS with Proton Therapy\",\"authors\":\"E. Hwang , S. Gaito , D. Thwaites , V. Ahern , E. Smith , G. Whitfield , P. Sitch , A. France , M. Aznar\",\"doi\":\"10.1016/j.ijrobp.2024.11.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>Recent work by the Pediatric Normal Tissue Effects in the Clinic (PENTEC) hearing loss task force provides guidance on benchmark dose constraints to reduce hearing loss but does not generate individualised risk estimations for patients. Uniquely, a risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our paediatric patient cohort treated with proton therapy (PT) for malignancies of the head and neck (H&N) or central nervous system (CNS).</div></div><div><h3>Methods</h3><div>This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 – Feb 2022 for malignancies of the H&N/CNS, either via the UK Proton Overseas Programme or at The Christie PT centre. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration.</div></div><div><h3>Results</h3><div>587 patients met inclusion criteria. Validation of the model demonstrated excellent discriminative ability, with an “optimal” cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe HI by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study.</div></div><div><h3>Conclusion</h3><div>The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.</div></div>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":\"121 3\",\"pages\":\"Page e3\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0360301624035909\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624035909","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:儿童临床正常组织效应(PENTEC)听力损失工作组最近的工作提供了基准剂量限制的指导,以减少听力损失,但没有为患者产生个性化的风险估计。独特的是,Keilty等人在2021年提出了一个风险计算模型,用于确定接受光子放射治疗的儿科患者发生严重听力障碍(HI)的可能性。本研究旨在验证他们的风险预测模型,用于我们接受质子治疗(PT)治疗头颈部(H&;N)或中枢神经系统(CNS)恶性肿瘤的儿科患者队列。方法:这是一项单机构研究,提取了2010年2月至2022年2月期间通过英国质子海外项目或克里斯蒂PT中心接受h&n /CNS恶性肿瘤PT治疗的所有年龄≤18岁患者的数据。提取需要输入Keilty模型的因素:PT时的年龄、PT结束后的时间、平均耳蜗剂量和铂化疗剂量。使用统计软件R v 4.3.1进行验证,分析事件判别和模型校准。结果587例患者符合纳入标准。模型的验证显示出出色的判别能力,“最佳”临界值为16%,特异性和敏感性为82%。然而,模型校准不太令人满意,表明与我们队列中临床观察到的事件相比,该模型高估了严重HI的风险,这可能与模型开发者和本研究之间事件评分的差异以及本研究的随访时间短有关。Keilty等人发表的(基于光子的)模型在PT背景下得到了验证,显示出高度判别能力,可以确定严重HI的高风险患者和低风险患者。然而,观察到的总体风险低于模型预测。
Identifying Pediatric Patients at Risk of Severe Hearing Impairment After Treatment for Malignancies of the H&N/CNS with Proton Therapy
Objectives
Recent work by the Pediatric Normal Tissue Effects in the Clinic (PENTEC) hearing loss task force provides guidance on benchmark dose constraints to reduce hearing loss but does not generate individualised risk estimations for patients. Uniquely, a risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our paediatric patient cohort treated with proton therapy (PT) for malignancies of the head and neck (H&N) or central nervous system (CNS).
Methods
This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 – Feb 2022 for malignancies of the H&N/CNS, either via the UK Proton Overseas Programme or at The Christie PT centre. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration.
Results
587 patients met inclusion criteria. Validation of the model demonstrated excellent discriminative ability, with an “optimal” cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe HI by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study.
Conclusion
The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.